Table 2.

The 2-, 3-, 5-, and 10-year overall survival (OS) rates for glioblastoma patients in clinical trials, registries and systematic reviews.

Patient Groups/Registries	2-Year OS Rate	3-Year OS Rate	5-Year OS Rate	10-Year OS Rate	References
RT-TMZ group versus RT only group	27.2% vs. 10.9%	16.0% vs. 4.4%	9.8% vs. 1.9%		[40]
RT-TMZ group versus RT only group in MGMT-unmethylated subgroup	14.8% vs. 1.8%	11.1% vs. 0%	8.3% vs. 0%
RT-TMZ group versus RT only group in MGMT-methylated subgroup	48.9% vs. 23.9%	27.6% vs. 7.8%	13.8% vs. 5.2%
RT-TMZ MGMT-methylated group	56%				[22]
RT-TMZ group (exploratory analysis)	31%	16%	5%		[1]
RT-TMZ plus placebo group	30.1%				[23]
The National Cancer Institute’s SEER Program (1985–2005, n = 5991)	9.5%	5.4%	3.6%	2.9%	[107]
The National Cancer Institute’s SEER Program (2005–2007)	24%				[108]
The Central Brain Tumor Registry of the United States (CBTRUS) (1995–2011, n = 30611)	14.8%	8.7%	5%	2.6%	[109]
Systematic reviews		2-5%		<1%	[110]